Home › Funds › Foresite Capital Management V, LLC › LYEL

Foresite Capital Management V, LLC position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

Foresite Capital Management V, LLC reported holding 476,386 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$6.7M, representing 1.85% of its reported portfolio and ranking #8 among its reported holdings. Foresite Capital Management V, LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)476.39K sh
Reported value held$6.69M
Portfolio Weight1.85%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Foresite Capital Management V, LLC's LYEL position evolved

Foresite Capital Management V, LLC first disclosed a stake in LYEL in Q4 2024 at 8,133,047 shares (US$5.2M). The position peaked in Q4 2025 at 477,078 shares, worth US$14.7M. Across 7 filings, Foresite Capital Management V, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 476,386 shares valued at US$6.7M. Notable position changes include a 95% trim in Q2 2025 (shares rose 84% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 8.13M $5.21M New
Q1 2025 8.13M $4.38M Hold
Q2 2025 406.65K $3.59M Reduce
Q3 2025 477.08K $7.75M Add
Q4 2025 477.08K $14.68M Hold
Q1 2026 477.08K $9.57M Hold
Q2 2026 476.39K $6.69M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has Foresite Capital Management V, LLC held LYEL?

Foresite Capital Management V, LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Foresite Capital Management V, LLC's current position in LYEL?

As of Q2 2026, Foresite Capital Management V, LLC holds 476.39K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $6.69M, representing 1.85% of its reported portfolio and ranking #8.

Has Foresite Capital Management V, LLC been buying or selling LYEL?

In the latest 13F filing (Q2 2026), Foresite Capital Management V, LLC held unchanged its position in LYEL. The position peaked in Q4 2025 at 477.08K shares.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Orland Properties Ltd, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.